Lyudmila Bazhenova, MD, discusses the FDA’s expanded approval of taletrectinib for ROS1-positive non–small cell lung cancer.
|Articles|May 12, 2015
- NSCLC (Issue 7)
- Volume 7
- Issue 2
Characteristics of Additional KRAS Subsets in Lung Cancer
Author(s)John Heymach, MD, PhD
John Heymach, MD, PhD, chair of Thoracic/Head and Neck Medical Oncology, MD Anderson Cancer Center, discusses the characteristics of three more KRAS subsets in lung cancer, which researchers discovered in a recent study.
Advertisement
John Heymach, MD, PhD, chair of Thoracic/Head and Neck Medical Oncology, MD Anderson Cancer Center, discusses the characteristics of three more KRAS subsets in lung cancer, which researchers discovered in a recent study.
<<<
Articles in this issue
over 11 years ago
MET as a Secondary Driver in Lung Cancerover 11 years ago
MiR-34a Link to PD-L1 May Mean New Immunotherapy in NSCLCover 11 years ago
More Endpoints Not Necessarily Merrier in NSCLC Drug Trialsover 11 years ago
Combining Bevacizumab With EGFR TKIs in Lung Cancerover 11 years ago
US-Cuban Partnership Developing Anticancer Vaccine for NSCLCAdvertisement
Related to this article
During a live event, Mary Jo Fidler, MD, and participants discussed how an intermediate-risk regimen, insurance resistance, and limited experience with trilaciclib shape neutropenia prevention in extensive-stage disease.
For Hispanic Heritage Month, Narjust Florez, MD, discusses lung cancer risk, biomarker testing, and trial access in Hispanic and Latinx patients.
A phase 2 trial is planned for an allogeneic CAR T-cell product in patients with lung or breast cancer with brain metastases.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dostarlimab Receives FDA Approval for MSI-H/dMMR Locally Advanced Rectal Cancer
2
Dr Bazhenova on the Updated FDA Label for Taletrectinib in ROS1+ NSCLC
3
FDA Accepts NDA for UGN-103 in Recurrent LG-IR-NMIBC
4
MC001 Receives FDA Fast Track Designation in Pancreatic Cancer
5